Navigation Links
Sanofi-aventis Oncology Data to be Presented at San Antonio Breast Cancer Symposium
Date:12/9/2010

with gemcitabine and carboplatin in the MDA-MB-468 (-) Triple Negative Breast Cancer (TNBC) cell lineIniparib Data:Abstract # P6-15-01

Gene pathway analysis of

primary TNBC tumors

Sunday, Dec. 12

7:00 - 8:30 AM CSTData from a preclinical study characterizing the pathways of  primary human triple-negative breast cancersAbout Iniparib (BSI 201)Iniparib (BSI-201), the United States Adopted Name (USAN) for BSI-201, is a novel investigational small molecule with poly (ADP-ribose) polymerase (PARP) inhibitory activity.

BiPar Sciences and sanofi-aventis are pursuing a broad development program with iniparib in breast cancer and multiple trials are planned to start in the next several months.  A Phase 3 trial in mTNBC is ongoing, and multiple new trials are planned to start in the next several months.  New trials include:

  • A Phase 2 trial in HER2-/Hormone receptor positive (ER+ and/or PR+) metastatic breast cancer
  • A Phase 1b/2 trial in HER2- metastatic breast cancer (combination with taxane chemotherapy)
  • A Phase 2 trial in mTNBC testing the Taxotere/Cytoxan chemotherapy combination

  • Iniparib also in being studied in a Phase 3 trial for patients with squamous non-small cell lung cancer, and in Phase 2 trials for patients with ovarian, uterine and brain cancers.  The regulatory submissions are planned for Q1 2011 in the U.S. and Q2 2011 in the European Union.  

    About Taxotere (docetaxel) Injection ConcentrateIntroduced more than 14 years ago, Taxotere is approved for use in the following indications:

    Breast Cancer:  

  • TAXOTERE is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy
  • TAXOTERE in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer

  • Non-Small Cell L
    '/>"/>

    SOURCE sanofi-aventis
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
    2. Covance and sanofi-aventis Finalize Agreements for 10-year Strategic R&D Alliance
    3. Sanofi-aventis to Acquire BMP Sunstone Creating a Strong Consumer Healthcare Platform in China
    4. Sanofi-aventis Initiates Phase III Study with Teriflunomide as Adjunct Therapy with Interferon Beta to Further Explore Clinical Benefits in Multiple Sclerosis
    5. Sanofi-aventis Commences Tender Offer to Acquire All Outstanding Shares of Genzyme for $69 per Share in Cash
    6. Covance and Sanofi-Aventis Sign Definitive Agreements for 10-Year Strategic R&D Alliance
    7. European Hospital Anticoagulant Market Dominated by Sanofi-Aventiss Clexane
    8. Reportlinker Adds Sanofi-Aventis: PharmaVitae Profile
    9. Sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme
    10. Sanofi-Aventis and Novalar File Marketing Authorization Application for OraVerse® in Five Key European Countries
    11. Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Orameds Oral Insulin Capsules
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)...   BioLife Solutions , Inc. (NASDAQ: ... of proprietary clinical grade cell and tissue ... media and a related cloud hosted biologistics ... shippers ("BioLife" or the "Company"), today announced ... company focused on developing and commercializing novel therapeutics ...
    (Date:8/29/2015)... 2015 La sofisticada aplicación ... sistemas de imagen por Ultrasonidos   ofrece resultados más ... rápidos y un flujo de trabajo   optimizado, lo ... proceso de detección de Cardiopatías   ... el lanzamiento europeo de HeartModel A.I ...
    (Date:8/28/2015)... , August 28, 2015 ... Market by Tumor (Breast, Lung, Prostate) Type (Protein & ... (Diagnostic, Drug Discovery, Prognostic) & Geography - Global Forecast ... is expected to reach around 17,689.0 Million USD by ... period of 2015 to 2020. Browse ...
    Breaking Medicine Technology:BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 2BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 3BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 4BioLife Solutions Customer TiGenix Phase 3 Clinical Trial Meets Primary Endpoint 5Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 2Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 3Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 4Cancer Biomarkers Market Worth 17,689.0 Million USD by 2020 5
    ... MacroChem Corporation (OTC,Bulletin Board: MACM) today announced results ... who completed a 48-week, U.S. multi-center,open-label efficacy and ... the treatment of onychomycosis (nail fungus). The composite,primary ... defined as,negative mycology (negative fungal culture and negative ...
    ... Sound Pharmaceuticals (SPI) has filed,an Investigational New ... of a proprietary formulation of ebselen for the ... oral capsule,containing ebselen, SPI-3005, will be tested in ... patients receiving platinum based chemotherapy.,This marks the second ...
    Cached Medicine Technology:MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2
    (Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... With the FCPX LUT Soft pack from ... LUT is a Lookup Table that contains a mathematical formula for modifying an image. The ... comes with 60 soft CUBE LUT files. , FCPX LUT Soft requires Final Cut ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Diablo Publications (DP), ... it has officially launched a new website and company identity ( diablopublications.com) . ... more closely aligned with the company’s strategic vision for growth and expansion over ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, ... ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, ... AdvantaClean’s National Call Center and website since Aug. 17. , The Greens have ...
    (Date:8/31/2015)... ... August 31, 2015 , ... Physicians’ ... Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® meeting, is seeking ... 6 in New York City. The annual legacy meeting uses a variety of ...
    (Date:8/31/2015)... ... August 31, 2015 , ... ... be at a greater risk for injury, potentially because they are more susceptible ... Pittsburgh Graduate School of Public Health analysis discovered. , The research, published ...
    Breaking Medicine News(10 mins):Health News:Pixel Film Studios, FCPX Plugin Developer, Releases FCPX LUT Soft 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 2Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 3Health News:Physicians’ Education Resource® Seeks Abstracts for the Upcoming Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® 4Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 2Health News:Television Viewing Linked to Higher Injury Risk in Hostile People 3
    ... states neglect preventing tobacco-caused illness , , TUESDAY, Jan. 13 ... U.S. government consistently failing grades for not protecting Americans ... American Lung Association,s State of Tobacco Control 2008 ... failed to enact critical policy measures, such as higher ...
    ... Weather Compound January,s Blood Drain NEW YORK, Jan. 13 ... operations (serving New York City, Long Island, Hudson Valley ... blood donations. Hospital demand for blood (needed for ... while levels of blood donation have been below forecast. ...
    ... General Practitioners (GPs) can delegate visits to patients and ... can provide care to more patients. Neeltje van den ... the "AGnES" project in the current edition of ... 2009; 106[1-2]: 3-9). , The change in the age ...
    ... Inc. today announced the,formation and launch of its newest ... to offer experienced and affordable custom,website design and marketing ... area. , Dr. Nino Doijashvilli, ... found a definite need for this service. Many ...
    ... Health announced today that the National Children,s Study will ... study of how genes and the environment interact to ... announced that the first phase of recruitment for the ... Queens, New York. The study will track ...
    ... 2009) The American Journal of Nursing ... publications of 2008 with an announcement today of its ... separate categories appear in the journal,s January issue. ... controversial consumer health topics and nursing industry issues that ...
    Cached Medicine News:Health News:U.S. Flunks on Tobacco Control Report Card 2Health News:U.S. Flunks on Tobacco Control Report Card 3Health News:U.S. Flunks on Tobacco Control Report Card 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 2Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 3Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 4Health News:Blood Emergency: Blood Supply Tips Into Danger Zone 5Health News:Tulip Systems Launches New Division: Atlanta Medical Websites 2Health News:National Children's Study Begins Recruiting Volunteers 2Health News:National Children's Study Begins Recruiting Volunteers 3Health News:National Children's Study Begins Recruiting Volunteers 4Health News:National Children's Study Begins Recruiting Volunteers 5Health News:American Journal of Nursing announces 2008 Book of the Year Awards 2
    ... (PTH) is synthesized by the parathyroid ... to decreased extracellular calcium concentrations. PTH ... and decreasing calcium excretion by the ... intact PTH is rapidly degraded into ...
    ACTIVATED CLOTTING TIME SYSTEM...
    ... Erythropoietin (EPO) is the primary known ... The predicted molecular weight of human EPO ... circulating form of EPO has an estimated ... itself appears to have a unique structure, ...
    ... versatility. Positron Corporation is the exclusive distributor ... whole body PET scanners. This unique performance ... quality images in clinical oncology, cardiology, and ... only scanner on the market that is ...
    Medicine Products: